ACAD - アカディア・ファ―マシュ―ティカルズ (ACADIA Pharmaceuticals Inc.)

ACADのニュース

   ACADIA Pharmaceuticals, Inc. (ACAD) CEO Stephen Davis on Q4 2021 Results - Earnings Call Transcript  2022/03/01 03:00:03 Seeking Alpha
   Acadia Pharma down 6% after hours after earnings misses  2022/02/28 21:52:02 Seeking Alpha
Shares of Acadia Pharma (ACAD) are down ~6% in post-market trading after its Q4 2021 results missed on the top and bottom lines.Net loss narrowed in the quarter 36% to ~$43.1M
   ACADIA Pharma GAAP EPS of -$0.27 misses by $0.04, revenue of $130.8M misses by $4.64M  2022/02/28 21:10:56 Seeking Alpha
ACADIA Pharma press release (ACAD): Q4 GAAP EPS of -$0.27 misses by $0.04.Revenue of $130.8M (+8.1% Y/Y) misses by $4.64M.2022 Financial Guidance: NUPLAZID net sales guidance…
   Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results  2022/02/28 21:05:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced financial results for the fourth quarter and full year ended December 31, 2021. “Acadia delivered strong fourth quarter and full year results with an increase in net sales of 10 percent year-over-year, driven by growth in both NUPLAZID prescriptions and market share,” said Steve Davis, Chief Executive Officer. “We recently resubmitted our sNDA for pimavanserin for Alzheimer’s disease psychosis to the FDA. In
   ACADIA Pharma Q4 2021 Earnings Preview (NASDAQ:ACAD)  2022/02/25 22:35:01 Seeking Alpha
ACADIA Pharma (NASDAQ:ACAD) is scheduled to announce Q4 earnings results on Monday, February 28th, after market close.The consensus EPS Estimate is -$0.24 and the consensus Revenue…
   ACADIA Pharmaceuticals (ACAD) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference  2022/01/12 21:24:38 Seeking Alpha
   Acadia, Stoke Team Up In $900M+ Deal On RNA Therapies For CNS Disorders  2022/01/10 13:11:12 Benzinga
Acadia Pharmaceuticals Inc (NASDAQ: ACAD ) and Stoke Therapeutics Inc (NASDAQ: STOK ) will team up on the treatments in rare genetic neurodevelopmental diseases of the CNS. The recently discovered SYNGAP1 syndrome will be first, followed by Rett syndrome (MECP2) and an undisclosed target the biotechs say is of mutual interest. “Combining Stoke’s capabilities with Acadia’s extensive expertise in … Full story available on Benzinga.com
   ACADIA Pharmaceuticals (NASDAQ:ACAD) Lowered to Neutral at Guggenheim  2021/12/24 08:08:41 Transcript Daily
Guggenheim cut shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) from a buy rating to a neutral rating in a research note issued to investors on Tuesday morning, Analyst Price Targets reports. They currently have $28.00 price objective on the biopharmaceutical companys stock. A number of other equities research analysts also recently issued reports on the stock. The []
   ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Forecasted to Earn FY2023 Earnings of ($0.80) Per Share  2021/12/24 07:10:42 Dakota Financial News
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Equities research analysts at Jefferies Financial Group lifted their FY2023 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a research note issued to investors on Monday, December 20th. Jefferies Financial Group analyst C. Howerton now expects that the biopharmaceutical company will earn ($0.80) per share for the []
   ACADIA Pharmaceuticals (NASDAQ:ACAD) PT Raised to $30.00  2021/12/24 06:32:41 Transcript Daily
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price objective hoisted by investment analysts at Canaccord Genuity from $26.00 to $30.00 in a report issued on Wednesday, Price Targets.com reports. The firm currently has a hold rating on the biopharmaceutical companys stock. Canaccord Genuitys price target indicates a potential upside of 23.46% from the stocks current price. ACAD []
   ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Is On The Rise  2021/12/01 14:00:00 Stocks Register
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) traded at $19.20 at close of the session on Tuesday, 11/30/21, made an upward move of 1.91% on its previous days price. Looking at the stock we see that its previous close was $18.84 and the beta (5Y monthly) reads 0.74 with the days price range being $18.57 $19.24. In ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Is On The Rise Read More »
   Insider Selling: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) President Sells 2,803 Shares of Stock  2021/11/24 01:26:43 Dakota Financial News
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) President Srdjan R. Stankovic sold 2,803 shares of the companys stock in a transaction dated Monday, November 22nd. The stock was sold at an average price of $19.01, for a total value of $53,285.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through []
   Parkinsons Disease Drugs Market to reach USD 8,383.2 Million by 2026 | Market Projection By Technology, Major key players, Growth, Revenue, CAGR, Regional Analysis, Industry Forecast  2021/11/15 09:08:00 Intrado Digital Media
Key Companies in Parkinsons Disease Drugs Market are Pfizer, Roche, Merck, Novartis, Orion Pharma, UCB, Teva Pharmaceutical, Vertical Pharmaceuticals, ACADIA Pharmaceuticals Inc., Impax Laboratories, Lundbeck and Others Key Players Key Companies in Parkinsons Disease Drugs Market are Pfizer, Roche, Merck, Novartis, Orion Pharma, UCB, Teva Pharmaceutical, Vertical Pharmaceuticals, ACADIA Pharmaceuticals Inc., Impax Laboratories, Lundbeck and Others Key Players
   ACADIA Pharmaceuticals Inc. Forecasted to Earn FY2021 Earnings of ($0.99) Per Share (NASDAQ:ACAD)  2021/11/13 08:02:44 Dakota Financial News
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Cantor Fitzgerald boosted their FY2021 earnings per share (EPS) estimates for ACADIA Pharmaceuticals in a research note issued on Tuesday, November 9th. Cantor Fitzgerald analyst C. Duncan now anticipates that the biopharmaceutical company will earn ($0.99) per share for the year, up from their prior forecast of ($1.20). Cantor Fitzgerald []
   ACADIA Pharmaceuticals Inc. to Post FY2021 Earnings of ($1.05) Per Share, SVB Leerink Forecasts (NASDAQ:ACAD)  2021/11/13 08:02:42 Transcript Daily
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Investment analysts at SVB Leerink lifted their FY2021 earnings per share estimates for shares of ACADIA Pharmaceuticals in a report issued on Monday, November 8th. SVB Leerink analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings of ($1.05) per share for the year, up from their prior []

calendar